Developing a Self-Administered Instrumented Motor Exam for Home-based Parkinson’s Disease Assessment Using Wearable Sensors (P3.043)

Objective: To develop a self-administered instrumented motor exam enabling remote measurement of Parkinson’s Disease (PD) signs. Background: Current methods for PD assessment in clinical trials rely on rating scales including the Movement Disorder Society Unified Parkinson’s Disease Rating Scale motor exam (MDS-UPDRS-III). The MDS-UPDRS-III requires in-clinic administration and assessment by neurologists creating significant burden for patients in upcoming disease-modification drug trials, which are likely to benefit from more frequent longitudinal measures. Wearable inertial sensors may be deployed to obtain a lower burden, more precise measurement of standardized exam movements in the home. Design/Methods: Twenty-nine mild to moderate PD patients (Hoehn & Yahr Results: Considering the MDS-UPDRS-III toe tapping task as an example , kinematic features (amplitude and temporal variability), and signal features (spectral entropy), varied significantly with the item-score (p 2 of .59. This approach is currently being applied to the other MDS-UPDRS-III items. Conclusions: We have developed an analytical framework that leverages data from wearable sensors to predict MDS-UPDRS-III item scores. This approach may enable frequent home-based assessments of PD motor function and more precise quantification of medication effects. Study Supported by: The study was supported by Pfizer Inc. Disclosure: Dr. Demanuele has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. & Biogen, Inc. Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc., MathWorks Inc. Dr. Ho has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Wacnik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, inc. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Kangarloo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Ramos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Volfson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Volfson holds stock and/or stock options in Pfizer Inc., which sponsored research in which Dr. Volfson was involved as an investigator. Dr. Volfson has received research support from Pfizer Inc. Dr. Bergethon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer and Biogen. Dr. Erb has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc.